.
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is currently underway in Chicago, bringing together oncology experts from around the world to showcase the latest advances in cancer research and treatment.At this year’s meeting, a research study conducted by Director Yajing Zhang and colleagues from Beijing GoBroad Boren Hospital was selected for poster presentation. The study addresses one of the most challenging questions in contemporary lymphoma care: Can patients with B-cell lymphoma who relapse or progress after CAR-T cell therapy still achieve meaningful responses through a redesigned treatment strategy based on alternative targets and sequential CAR-T approaches?
CAR-T cell therapy has become a transformative treatment option for many patients with relapsed or refractory B-cell malignancies. However, a substantial proportion of patients eventually experience relapse, disease progression, or loss of durable benefit following treatment. For these patients, therapeutic options are limited, disease progression is often rapid, and clinical management remains highly challenging.
The study presented at ASCO was designed to address this critical unmet need. Rather than simply repeating the original CAR-T approach, the investigators explored a strategy of sequential multi-antigen CAR-T retreatment, selecting alternative targets based on individual disease characteristics, prior treatment history, anticipated antigen expression profiles, and overall clinical risk.
Study Design
Focusing on High-Risk Patients After CAR-T Failure
This investigator-initiated, single-center Phase I/II study enrolled patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who had experienced disease progression after receiving at least one prior CAR-T cell infusion.
Participants subsequently received autologous CAR-T products employing alternative therapeutic targets. Depending on individual disease characteristics, treatment strategies included switching to different antigens such as CD20, CD22, and CD79b, or, in selected circumstances, re-challenging previously targeted antigens using modified CAR constructs.
At the time of data cutoff, 26 patients had been enrolled, including:
- 18 patients with diffuse large B-cell lymphoma (DLBCL)
- 6 patients with primary central nervous system lymphoma (PCNSL)
- 2 patients with Burkitt lymphoma
The median number of prior treatment lines was five (range: 3–8), highlighting the heavily pretreated and highly refractory nature of this patient population.
Notably, the study included patients with primary CNS lymphoma, a subgroup that remains particularly difficult to treat because of limited therapeutic options and poor outcomes after relapse.
Study Results
High Response Rates with Manageable Toxicity
After a median follow-up of 10.2 months, the investigators observed encouraging clinical activity.
Among the 26 treated patients:
- Overall response rate (ORR): 88.5%
- Complete response (CR) rate: 73.1%
Promising activity was also observed in patients with primary CNS lymphoma, where 5 of 6 patients achieved complete remission.
Regarding safety, treatment-related toxicities were generally manageable.
Cytokine release syndrome (CRS) was relatively common but was predominantly limited to grade 1–2 events. No grade 3 or higher CRS was reported.
Similarly, immune effector cell-associated neurotoxicity syndrome (ICANS) occurred infrequently and was limited to grade 1 events, with no cases of grade 2 or higher neurotoxicity observed.
Hematologic toxicities were also considered manageable within the context of this heavily pretreated population.
The investigators emphasized that these findings arise from an early-phase study with a limited sample size and should not be interpreted as evidence that sequential CAR-T therapy is appropriate for all patients who relapse after CAR-T treatment.
The mechanisms underlying post–CAR-T relapse are complex and may involve:
- Antigen loss
- Reduced antigen expression
- Changes in the tumor microenvironment
- CAR-T cell exhaustion
- Intrinsically aggressive disease biology
Consequently, post–CAR-T management requires individualized therapeutic planning rather than simply repeating a previous CAR-T regimen.
Expert Perspective
After CAR-T Failure, the Goal Is Not Repetition—It Is Redesign
According to Director Zhang and her team, relapse after CAR-T therapy does not necessarily signify the end of immunotherapeutic opportunities. At the same time, retreatment should not be viewed as merely repeating the original intervention.
The clinically meaningful approach is to comprehensively reassess each patient’s prior treatment course, disease progression pattern, antigen expression profile, and overall risk factors, and then redesign the treatment pathway accordingly.
For some patients, malignant cells continue to express actionable B-cell antigens or may remain susceptible to alternative targets. In such cases, changing antigen targets, modifying CAR constructs, and employing sequential multi-antigen strategies may provide new therapeutic opportunities.
This approach may be particularly valuable for patients who have exhausted multiple prior lines of therapy and have few remaining treatment options.
The investigators also stressed that post–CAR-T retreatment requires highly specialized clinical management. These patients frequently present with substantial tumor burden, elevated infection risk, and cumulative toxicities from previous therapies.
Comprehensive assessment before retreatment should include:
- Bone marrow reserve
- Infection status
- Organ function
- Neurologic risk factors
- Prior CAR-T–related toxicities
During treatment, close monitoring is required for CRS, ICANS, hematologic toxicities, and infectious complications. Long-term follow-up is equally important to evaluate response durability, immune reconstitution, and late safety outcomes.
Scientific Significance
A New Direction for Patients Relapsing After CAR-T Therapy
The significance of this study lies not in establishing a new standard of care, but in demonstrating that selected patients who relapse after CAR-T therapy may still benefit from subsequent cellular immunotherapy when treatment strategies are carefully redesigned.
The findings raise several important clinical questions that warrant further investigation:
- Which patients remain suitable candidates for additional cellular therapy after CAR-T failure?
- How should antigen selection be optimized based on disease biology and antigen expression patterns?
- How can response rates be improved while maintaining long-term safety and durable benefit?
Larger studies with longer follow-up and multicenter participation will be needed to better define the patient populations most likely to benefit, identify optimal target combinations, determine the best timing for intervention, and refine safety management strategies.
Conclusion
CAR-T therapy continues to reshape the treatment landscape for hematologic malignancies, yet relapse after CAR-T remains a major global challenge.
The study presented by Director Zhang and colleagues at ASCO suggests that sequential multi-antigen CAR-T retreatment may offer a promising therapeutic option for selected patients with B-cell lymphoma who have previously failed CAR-T therapy.
Perhaps more importantly, the study delivers a nuanced and clinically valuable message: relapse after CAR-T does not necessarily mean that all therapeutic options have been exhausted, but neither should retreatment be approached through simple repetition. Only through comprehensive antigen assessment, risk stratification, treatment-pathway redesign, and expert multidisciplinary management can patients be offered the most rational and effective subsequent treatment strategies.
